DRMAW
Dermata Therapeutics, Inc. [DRMAW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
DRMAW Stock Summary
In the News
DRMAW Financial details
Company Rating
-
Market Cap
1.75M
Income
-7.76M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-0.26
Forward P/E
-
PEG
0.04
P/S
-
P/B
0.29
P/C
-
P/FCF
-0.3
Quick Ratio
7.23
Current Ratio
7.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.94
EPS next Y
-
EPS next Q
-
EPS this Y
-80.82%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-98%
ROE
-101%
ROC
-1.18%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0092-0.0092
52W High
-
52W Low
-
RSI
49
Rel Volume
-
Avg Volume
-
Volume
19.61K
Perf Week
26.58%
Perf Month
45.99%
Perf Quarter
-
Perf Half Y
-22.87%
-
-
-
-
Beta
0.872
-
-
Volatility
0%, 0%
Prev Close
24.22%
Price
0.02
Change
6.38%
Company Profile
- Market Capitalization 1.75M
- Employee 8
- CEO Mr. Gerald T. Proehl
- Headquarters San Diego,CA,US
- IPO Date 2021-08-13
-
Website
http://www.dermatarx.com 
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
